Pharmfactor Spółka z Ograniczoną Odpowiedzialnością (KRS 0000690179, NIP 8943111912) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. PHARMFACTOR operates in: Manufacture of basic pharmaceutical products (PKD 21.10.Z). Industry: Pharmaceuticals. The company has been listed in the National Court Register since August 10, 2017.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Pharmfactor
Identity
- Name
- Pharmfactor Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- August 10, 2017
- Registry status as of
- December 3, 2025
- Latest entry
- July 4, 2025
- Founding act
- 26.07.2017 R., NOTARIUSZ PRZEMYSŁAW SZOCIŃSKI, KANCELARIA NOTARIALNA W JELENIEJ GÓRZE, REP. A NR 4368/2017
Articles of association history (2)
- July 26, 2017: 26.07.2017 R., NOTARIUSZ PRZEMYSŁAW SZOCIŃSKI, KANCELARIA NOTARIALNA W JELENIEJ GÓRZE, REP. A NR 4368/2017
- December 20, 2019: 20.12.2019R., NOTARIUSZ MAŁGORZATA BAŃKOSZ-RUŚKOWSKA, KANCELARIA NOTARIALNA WE WROCŁAWIU, REP. A NR 9733/2019, ZMIANA: § 8, § 9 I § 11 PKT 5 UMOWY SPÓŁKI
Activities
Main activity
21.10.ZManufacture of basic pharmaceutical products
Other activities
Address and contact
- Address
- UL. MUCHOBORSKA, 6, 54-424, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-85323-51247-HAVCR-28
- Coordinates
- 51.1100, 17.0319approx.
Operational status - Pharmfactor
Founded
August 10, 2017
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
21.10.Z
Manufacture of basic pharmaceutical products
Share capital
4.6 M PLN
Shareholders
1
shareholder
Board
1 person
Sup. board: 3 · Proxies: 3
Filed years
N/A
Registry entries
33
latest: July 4, 2025
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Pharmfactor.
No ratings
Related articles
News
Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss
Warsaw-based Bioton S.A. (KRS 0000214072) - the only Polish manufacturer of biosynthetic human insulin - closed 2025 with revenue of PLN 235.9 m and EBITDA of PLN 53.82 m (margin 18.72%), but a net loss of around PLN -16.4 m keeps the company in the red. EBITDA improved 76% versus 2024 (PLN 30.6 m), driven by international expansion (Malaysia ~PLN 100 m a year) and a contract to produce the insulin analogue Glargine. Yifan Pharmaceutical controls 31.65% of capital indirectly.
News
Celon Pharma 2025: record PLN 244 m revenue, but net loss deepens to PLN 79.4 m - the 2026 outlook hinges on Salmex registration in China and the GLP-1 programme
Celon Pharma S.A. (KRS 0000437778, Kiełpin/Łomianki) closed 2025 with consolidated revenue of PLN 244.34 m (+17.9% YoY), EBITDA of PLN 21.42 m (+42%) and a deepened net loss of PLN -79.36 m (vs PLN -34.45 m a year earlier). The deeper loss reflects spending on the innovative GLP-1 segment. The generics segment grows (+15.3%) and represents 84.4% of revenue. Salmex registration in China is expected by end-2026. Maciej Wieczorek controls 58.8% of capital and 68.2% of voting rights through Glatton sp. z o.o.
